A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Clinical trial NCT04988555 · RECRUITING

Trial details

NCT number: NCT04988555
Sponsor: Sumitomo Pharma America, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute Leukemia, Lymphocytic, Acute Multiple Myeloma Myelodysplastic Syndromes

Start date: 2022-02-28
Primary completion: 2027-06-30
Enrollment: 606

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.